Skip to main content
In stock | Targeted Therapy

Sorafenib (AML use)

Oncology Type Hematologic (AML)
Drug Class / Mechanism FLT3 Inhibitor
No Image
Description

Sorafenib (AML use) is classified as a FLT3 Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy
Oncology Type Hematologic (AML)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3